Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926271 | 0.84 | CYP3A4 (0.40) | ESR2TYRCYP3A4ALOX15TSHR | |
| SCHEMBL13802056 | 0.81 | TYR (0.41) | ESR2ESR1HSD17B1TYRNR3C1 | |
| SCHEMBL11115074 | 0.80 | GABRA1 (0.46) | ESR2ESR1TYR | |
| SCHEMBL933119 | 0.79 | TYR (0.58) | TYRCYP3A4ALOX15TSHR | |
| SCHEMBL30513627 | 0.79 | TYR (0.58) | TYRCYP3A4ALOX15TSHR | |
| SCHEMBL31176234 | 0.79 | SRC (0.42) | NR3C1PGRNR3C2 | |
| SCHEMBL2561411 | 0.79 | SRC (0.42) | NR3C1PGRNR3C2 | |
| SCHEMBL31305640 | 0.79 | ESR2 (0.47) | ESR2ESR1HSD17B1TYRNR3C1 | |
| SCHEMBL2018825 | 0.79 | ESR2 (0.47) | ESR2ESR1HSD17B1TYRNR3C1 | |
| SCHEMBL8752791 | 0.76 | TYR (0.58) | ESR2ESR1TYRCYP3A4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561560-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026034-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4041262-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072269-A1 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-2328867-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| EP-0760811-B1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 MODULATORS | INST NAT SANTE RECH MED (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1066261-A1 | PYRIDINE DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999048871-A1 | PYRIDINE DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-30 | — | — | WO | disclosed |
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | disclosed |